Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXFI90)

Drug Name

oxazine 89 Drug Info

Synonyms

CHEMBL2347208; N-{3-[(4s,6s)-2-Amino-4-Methyl-6-(Trifluoromethyl)-5,6-Dihydro-4h-1,3-Oxazin-4-Yl]-4-Fluorophenyl}-5-Cyanopyridine-2-Carboxamide; oxazine 89; GTPL6944; SCHEMBL15991481; BDBM50432601; 1HL

Indication

Disease Entry	ICD 11	Status	REF
Diabetic nephropathy	GB61.Z	Clinical trial	[1]

Cross-matching ID

PubChem CID: 71305058
TTD Drug ID: DMXFI90

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-secretase (BACE)	TT8JRS7	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Beta-secretase (BACE)	DTT	BACE	5.928	4.638	6.443	5.3

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Diabetic nephropathy

ICD Disease Classification

GB61.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Beta-secretase (BACE)	DTT	NO-GeName	6.98E-04	1.03	2.84

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J Med Chem. 2013 May 23;56(10):3980-95.